CN105143251B - 流感核蛋白疫苗 - Google Patents

流感核蛋白疫苗 Download PDF

Info

Publication number
CN105143251B
CN105143251B CN201480013364.1A CN201480013364A CN105143251B CN 105143251 B CN105143251 B CN 105143251B CN 201480013364 A CN201480013364 A CN 201480013364A CN 105143251 B CN105143251 B CN 105143251B
Authority
CN
China
Prior art keywords
influenza
antigen
imx313t
npm
tpa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480013364.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105143251A (zh
Inventor
J·德尔坎波阿斯卡拉泰尔
F·希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ossie Huaco J Co
Original Assignee
Ai Makexiou
Ossie Huaco J Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Makexiou, Ossie Huaco J Co filed Critical Ai Makexiou
Priority to CN202110430609.2A priority Critical patent/CN113307881A/zh
Publication of CN105143251A publication Critical patent/CN105143251A/zh
Application granted granted Critical
Publication of CN105143251B publication Critical patent/CN105143251B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480013364.1A 2013-03-18 2014-03-18 流感核蛋白疫苗 Active CN105143251B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110430609.2A CN113307881A (zh) 2013-03-18 2014-03-18 流感核蛋白疫苗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305320.7 2013-03-18
EP13305320 2013-03-18
PCT/EP2014/055438 WO2014147087A1 (en) 2013-03-18 2014-03-18 Influenza nucleoprotein vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110430609.2A Division CN113307881A (zh) 2013-03-18 2014-03-18 流感核蛋白疫苗

Publications (2)

Publication Number Publication Date
CN105143251A CN105143251A (zh) 2015-12-09
CN105143251B true CN105143251B (zh) 2021-05-11

Family

ID=48044708

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480013364.1A Active CN105143251B (zh) 2013-03-18 2014-03-18 流感核蛋白疫苗
CN202110430609.2A Pending CN113307881A (zh) 2013-03-18 2014-03-18 流感核蛋白疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110430609.2A Pending CN113307881A (zh) 2013-03-18 2014-03-18 流感核蛋白疫苗

Country Status (11)

Country Link
US (2) US9243047B2 (enExample)
EP (1) EP2976357B1 (enExample)
JP (1) JP2016520534A (enExample)
KR (1) KR102379951B1 (enExample)
CN (2) CN105143251B (enExample)
AU (1) AU2014234363B2 (enExample)
BR (1) BR112015023738B8 (enExample)
CA (1) CA2901888C (enExample)
MX (1) MX363149B (enExample)
RU (1) RU2662667C2 (enExample)
WO (1) WO2014147087A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677799C2 (ru) * 2012-12-11 2019-01-21 Озивакс Сас Модифицированные суперспиральные белки с улучшенными свойствами
WO2020210003A2 (en) * 2019-03-21 2020-10-15 Georgia State University Research Foundation, Inc. Virus-like particles and uses thereof
CA3230305A1 (en) 2021-08-24 2023-03-02 Osivax Belgique Immunogenic compositions and their use
CA3242433A1 (en) 2021-12-22 2023-06-29 Osivax Vaccine compositions and their use
CA3253732A1 (en) 2022-03-22 2023-09-28 Osivax mRNA VACCINE COMPOSITIONS AND THEIR USE
CN115779079A (zh) * 2022-10-01 2023-03-14 中国人民解放军军事科学院军事医学研究院 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白
CN117659138B (zh) * 2023-12-25 2025-04-08 华中农业大学 一种流感病毒np蛋白突变体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014654A2 (en) * 2003-08-12 2005-02-17 Avidis Sa Product comprising a c4bp core protein and a monomeric antigen, and its use
CN101384617A (zh) * 2005-11-30 2009-03-11 艾马克西奥公司 抗原和佐剂的多聚体复合物
CN102666575A (zh) * 2009-10-16 2012-09-12 艾西斯创新有限公司 分枝杆菌疫苗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0620277A1 (en) * 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
WO1999012036A1 (en) * 1997-09-04 1999-03-11 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
US20070104726A1 (en) * 2002-08-14 2007-05-10 Avidis Sa Multimeric complexes of antigens and adjuvants
EP2060586A1 (en) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use
RU2677799C2 (ru) * 2012-12-11 2019-01-21 Озивакс Сас Модифицированные суперспиральные белки с улучшенными свойствами

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014654A2 (en) * 2003-08-12 2005-02-17 Avidis Sa Product comprising a c4bp core protein and a monomeric antigen, and its use
CN101384617A (zh) * 2005-11-30 2009-03-11 艾马克西奥公司 抗原和佐剂的多聚体复合物
CN102666575A (zh) * 2009-10-16 2012-09-12 艾西斯创新有限公司 分枝杆菌疫苗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMX-DogTag [synthetic construct];GenBank;《GenBank》;20190321;QBO24245.1 *

Also Published As

Publication number Publication date
CA2901888A1 (en) 2014-09-25
AU2014234363B2 (en) 2018-02-15
BR112015023738A2 (pt) 2017-11-21
BR112015023738B1 (pt) 2023-01-10
WO2014147087A1 (en) 2014-09-25
CN113307881A (zh) 2021-08-27
US20150098958A1 (en) 2015-04-09
EP2976357B1 (en) 2018-10-17
CA2901888C (en) 2023-06-20
US20160215032A1 (en) 2016-07-28
RU2662667C2 (ru) 2018-07-26
EP2976357A1 (en) 2016-01-27
JP2016520534A (ja) 2016-07-14
MX2015013304A (es) 2015-12-15
KR20150131292A (ko) 2015-11-24
CN105143251A (zh) 2015-12-09
MX363149B (es) 2019-03-11
BR112015023738B8 (pt) 2023-02-14
AU2014234363A1 (en) 2015-09-03
US9963490B2 (en) 2018-05-08
US9243047B2 (en) 2016-01-26
KR102379951B1 (ko) 2022-03-31
RU2015140603A (ru) 2017-04-21

Similar Documents

Publication Publication Date Title
EP3166963B1 (en) Influenza virus vaccines and uses thereof
CN104066446B (zh) 流感病毒疫苗及其用途
CN105143251B (zh) 流感核蛋白疫苗
US10328144B2 (en) Influenza virus vaccines and uses thereof
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
Deng et al. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge
JP2013523096A (ja) インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用
JP2023525050A (ja) キメラインフルエンザワクチン
Baranowska et al. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8+-mediated cross protection against influenza
WO2011056802A1 (en) Influenza virus recombinant proteins
CA3221953A1 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
RU2776479C1 (ru) Живая пробиотическая вакцина, содержащая консервативные эпитопы вируса гриппа А (LAH+4M2e), для профилактики гриппозной инфекции
RU2777061C2 (ru) Живая пробиотическая вакцина для профилактики инфекции, вызванной вирусом гриппа
ES2719256T3 (es) Proteínas de tipo superhélice modificadas que presentan unas propiedades mejoradas
HK1236966B (en) Influenza virus vaccines and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180129

Address after: France

Applicant after: Ossie Huaco J company

Address before: France

Applicant before: IMAXIO

GR01 Patent grant
GR01 Patent grant